AAA
SGMT icon

Affinity Asset Advisors’s Sagimet Biosciences SGMT Stock Holding History

Affinity Asset Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.54M Sell
868,020
-280,225
-24% -$1.56M 0.23% 72
2025
Q4 		$6.8M Buy
1,148,245
+798,245
+228% +$5.74M 0.39% 54
2025
Q3 		$2.4M Buy
+350,000
New +$2.84M 0.21% 72

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Affinity Asset Advisors's SGMT Position: Q1 2026 in Review

Affinity Asset Advisors reduced its Sagimet Biosciences (SGMT) stake by 24% in Q1 2026, selling an estimated $1.56M and leaving 868,020 shares worth $4.54M. The position accounts for 0.23% of the portfolio, ranked #72.

Affinity Asset Advisors first reported a position in SGMT in Q3 2025 and has held it in 3 quarters since. The position peaked at $6.8M in Q4 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Affinity Asset Advisors held 868,020 shares of Sagimet Biosciences worth $4.54M as of Q1 2026.
  • Affinity Asset Advisors sold 280,225 Sagimet Biosciences shares in Q1 2026, an estimated $1.56M.
  • Sagimet Biosciences made up 0.23% of Affinity Asset Advisors's portfolio in Q1 2026, its #72 holding.
  • Affinity Asset Advisors first reported a position in Sagimet Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Affinity Asset Advisors's Sagimet Biosciences position peaked at $6.8M in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.